Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Hunan Nucien Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688189'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -27.6 Med: 0.86 Max: 14.12
Current: -18.79
During the past 10 years, Hunan Nucien Pharmaceutical Co's highest Return-on-Tangible-Asset was 14.12%. The lowest was -27.60%. And the median was 0.86%.
SHSE:688189's Return-on-Tangible-Asset is ranked worse than 82.8% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.05
vs SHSE:688189: -18.79
Hunan Nucien Pharmaceutical Co (SHSE:688189) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Hunan Nucien Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Hunan Nucien Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Nucien Pharmaceutical Co Return-on-Tangible-Asset Chart
SHSE:688189 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Nucien Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Nucien Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Nucien Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Hunan Nucien Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -9.00% mean?
Hunan Nucien Pharmaceutical Co (SHSE:688189) has a Return-on-Tangible-Asset of -9.00% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hunan Nucien Pharmaceutical Co and its competitors. According to the industry distribution chart, Hunan Nucien Pharmaceutical Co ranks #833 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 82.8%.
Is Hunan Nucien Pharmaceutical Co's Return-on-Tangible-Asset too high?
Hunan Nucien Pharmaceutical Co's current Return-on-Tangible-Asset is -9.00%. Based on the distribution chart, Hunan Nucien Pharmaceutical Co ranks #833 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hunan Nucien Pharmaceutical Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Nucien Pharmaceutical Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hunan Nucien Pharmaceutical Co ranks #833 out of 1006 companies for Return-on-Tangible-Asset. This places Hunan Nucien Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.05, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hunan Nucien Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Nucien Pharmaceutical Co's current Return-on-Tangible-Asset is -9.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Nucien Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co (SHSE:688189) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥2.31, compared to a current price of ¥6.42 — trading 177.9% above its estimated fair value. The current Return-on-Tangible-Asset is -9.00%. Hunan Nucien Pharmaceutical Co's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Hunan Nucien Pharmaceutical Co (SHSE:688189), the current Return-on-Tangible-Asset is -9.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Nucien Pharmaceutical Co (SHSE:688189) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥6.42 is trading 177.9% above its estimated GF Value™ of ¥2.31.
GuruFocus considers Hunan Nucien Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:688189:
Return-on-Tangible-Asset: -9.00%
GF Value™: ¥2.31 vs. price of ¥6.42 (177.9% above fair value)
No single metric tells the full story. See the SHSE:688189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Nucien Pharmaceutical Co Ltd is a pharmaceutical company integrating drug research and development, production and sales. The company focuses on anti-infection, cardio-cerebral vascular, anti-tumor and other pharmaceutical fields. The company's business scope includes the manufacturing and sales of chemical pharmaceutical preparations, chemical pharmaceutical raw materials, biological drugs, chemical reagents, and auxiliaries.
52GF Score
Get the complete analysis for SHSE:688189
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688189 has been successfully added to your 
